文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌高剂量率近距离放疗推量:不同大分割方案组合与临床结局

High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes.
PubMed 文献 · Radiother Oncol · 2017-06-23

该研究回顾了1999至2011年间832例接受外照射放疗(EBRT)联合高剂量率近距离放疗(HDR-BT)推量的局限性前列腺癌患者,将不同方案按生物有效剂量(BED)分为三组。结果显示,BED>260Gy组5年PSA<0.2ng/ml的比例显著高于低BED组(86.7% vs 68.6%,p=0.005),但≥3级晚期泌尿生殖毒性略有增加。

要点

  • BED>260Gy组5年PSA<0.2ng/ml比例达86.7%,高于BED<250Gy组的68.6%。
  • BED>260Gy组≥3级晚期泌尿生殖毒性发生率为4.9%。
  • BED>260Gy与5年PSA≥0.2ng/mL风险降低独立相关(OR 0.350,p=0.011)。

核心结论

  • 大分割方案提高BED与生化控制改善相关,泌尿毒性小幅增加但临床可接受。

研究设计与样本

  • 1999至2011年832例局限性前列腺癌患者接受不同方案EBRT联合HDR-BT,按BED分为三组进行回顾性比较。

主要发现

  • 全队列5年、10年生化失败无生存率(BFFS,Phoenix定义)分别为94.6%和92.5%,总生存率(OS)分别为96.1%和80.3%,前列腺癌特异性生存率(PCSS)分别为99.5%和97.8%。
  • 5年PSA<0.2ng/ml的患者比例在BED<250、250-260、>260Gy组分别为68.6%、78.7%、86.7%(p=0.005)。
  • 5年BFFS(Phoenix定义)在BED<250、250-260、>260Gy组分别为97.3%、94.3%、94.9%(p=0.453)。
  • 多因素logistic回归显示,BED>260Gy组相对于BED<250Gy组保持5年PSA<0.2ng/mL的OR为0.350(p=0.011)。
  • ≥3级急性泌尿生殖毒性在BED>260Gy组有2例(4.7%);≥3级晚期泌尿生殖毒性在250-260Gy组有6例(1.7%),>260Gy组有9例(4.9%)。

临床怎么用

  • 采用HDR-BT推量时,可考虑将BED提高至>260Gy以改善生化控制,同时关注泌尿毒性。

局限性

  • 回顾性研究,不同放疗方案按BED分组比较,可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the outcomes of our high-dose-rate brachytherapy (HDR-BT) boost experience in localized prostate cancer treated with different combinations of radiation doses and fractionation. MATERIAL AND METHODS: Between 1999 and 2011, 832 patients were treated with different regimens of external beam radiotherapy (EBRT) and HDR-BT. These regimens were converted into three biologically effective dose (BED) groups. The biochemical failure-free survival (BFFS), reported with the phoenix definition and prostate-specific antigen (PSA) >0.2ng/ml at 5-year, genitourinary (GU) and gastrointestinal (GI) toxicities were compared between the groups. RESULTS: The 5-, 10-year BFFS for the entire cohort were 94.6% and 92.5%, for overall survival (OS) 96.1% and 80.3% and for prostate cancer-specific survival (PCSS) 99.5% and 97.8%. The percentage of patients with a 5-year PSA level <0.2ng/ml was 68.6%, 78.7% and 86.7% in the BED group of <250, 250-260 and >260Gy (p=0.005) while the 5-year BFFS rates according to phoenix definition were 97.3%, 94.3% and 94.9% for BED group <250, 250-260 and >260Gy (p=0.453). On multivariate logistic regression, patients in the BED>260Gy group were significantly more likely to remain free from 5-year PSA values ≥0.2ng/mL compared with those in the BED<250Gy group (OR: 0.350, p=0.011). Grade≥3 acute GU toxicity was reported in 2 patients (4.7%) for BED>260Gy while grade≥3 late GU toxicity was reported in 6 (1.7%) and 9 (4.9%) patients for 250-260Gy and >260Gy BED groups. CONCLUSIONS: The increase in BED with the hypofractionated regimens correlates with an improvement in biochemical control with of urinary toxicity. This increase in urinary toxicity is small and clinically acceptable.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Vigneault E, Mbodji K, Magnan S, et al. High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes. Radiother Oncol. 2017. PMID: 28652094. doi:10.1016/j.radonc.2017.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。